Marshall Wace
ACOR

Marshall Wace’s Acorda Therapeutics ACOR Stock Holding History

Marshall Wace’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,194
Closed -$293K – 2178
2019
Q4 		$293K Sell
1,194
-959
-45% -$242K ﹤0.01% 1285
2019
Q3 		$741K Sell
2,153
-1,530
-42% -$832K 0.01% 1008
2019
Q2 		$3.39M Sell
3,683
-1,182
-24% -$1.45M 0.03% 609
2019
Q1 		$7.76M Buy
4,865
+1,543
+46% +$2.78M 0.07% 326
2018
Q4 		$6.21M Buy
+3,322
New +$7.23M 0.06% 388
2016
Q3 		– Sell
-299
Closed -$916K – 1183
2016
Q2 		$916K Buy
299
+179
+149% +$582K 0.01% 729
2016
Q1 		$382K Buy
+120
New +$498K ﹤0.01% 892
2014
Q4 		– Sell
-1,209
Closed -$4.91M – 1022
2014
Q3 		$4.91M Buy
+1,209
New +$4.54M 0.07% 291

Other funds holding ACOR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Marshall Wace's ACOR Position: Q1 2020 in Review

Marshall Wace sold out of Acorda Therapeutics (ACOR) in Q1 2020, closing a stake of 1,194 shares — an estimated $293K sold.

Marshall Wace first reported a position in ACOR in Q3 2014 and held it in 8 quarters. The position peaked at $7.76M in Q1 2019. 106 funds tracked by Wall St. Rank hold ACOR as of Q1 2020.

  • Marshall Wace reported no remaining Acorda Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Marshall Wace sold 1,194 Acorda Therapeutics shares in Q1 2020, an estimated $293K.
  • Marshall Wace first reported a position in Acorda Therapeutics in Q3 2014 and held it in 8 quarters.
  • Marshall Wace's Acorda Therapeutics position peaked at $7.76M in Q1 2019.
  • 106 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2020.

Based on Marshall Wace's 13F filing for Q1 2020, filed 15 May 2020.